CAR T cell therapy for multiple myeloma: where are we now and where are we headed?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

CAR T cell therapy for multiple myeloma: where are we now and where are we headed?

Published:2017-11-06 Issue:9 Volume:59 Page:2056-2067
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Ghosh Arnab¹,Mailankody Sham²,Giralt Sergio A.³⁴,Landgren C. Ola²^ORCID,Smith Eric L.²⁴,Brentjens Renier J.⁴⁵

Affiliation:

1. Hematology/Oncology/BMT Fellowship Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA;

2. Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA;

3. Adult BMT Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA;

4. Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA;

5. Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2017.1393668

Reference102 articles.

1. Improved survival in multiple myeloma and the impact of novel therapies

2. Minimal residual disease in multiple myeloma: bringing the bench to the bedside

3. A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival

4. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma

5. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-BCMA CAR-T cell-based therapies and bispecific antibodies in the immunotherapy era: are we ready for this?;Expert Review of Hematology;2024-05-21

2. A Review of Immunotherapy in the Treatment of Tumors;Immunology Studies;2024

3. CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond;Vaccines;2023-11-16

4. Combination Treatment Targeting mTOR and MAPK Pathways Has Synergistic Activity in Multiple Myeloma;Cancers;2023-04-19

5. Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies;Stem Cell Research & Therapy;2022-09-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3